International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV)

Content and implementation in daily routine practice

Karin Jordan, Richard J. Gralla, Franziska Jahn, Alex Molassiotis

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Over the past decades major improvements in the management of chemotherapy induced nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV can be prevented in almost 70%, and even up to, 80% of patients. Treatment guidelines enable physicians to integrate the latest clinical research into their daily practice. The large volume of rapidly evolving clinical data has been summarised and incorporated into treatment recommendations by well-known and reliable institutions. These organisations include the Multinational Association of Supportive Care in Cancer (MASCC), the European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN). However, despite the availability of these guidelines, there is an emerging evidence that adherence to, and implementation of, treatment recommendations is less than optimal. This review will especially focus on the content of the current antiemetic guidelines and will address the important question of how these guidelines are implemented in routine practice.

Original languageEnglish (US)
Pages (from-to)197-202
Number of pages6
JournalEuropean Journal of Pharmacology
Volume722
Issue number1
DOIs
StatePublished - Feb 5 2014

Fingerprint

Antiemetics
Nausea
Vomiting
Guidelines
Drug Therapy
Medical Oncology
Neoplasms
Therapeutics
Physicians
Research

Keywords

  • 5-HT serotonin receptor antagonists
  • Antiemetic therapy
  • ASCO antiemetic guidelines
  • MASCC/ESMO antiemetic guidelines
  • NCCN practice antiemesis guidelines
  • Neurokinin receptor antagonist

ASJC Scopus subject areas

  • Pharmacology

Cite this

International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV) : Content and implementation in daily routine practice. / Jordan, Karin; Gralla, Richard J.; Jahn, Franziska; Molassiotis, Alex.

In: European Journal of Pharmacology, Vol. 722, No. 1, 05.02.2014, p. 197-202.

Research output: Contribution to journalArticle

@article{78615ba5b1954fe2af91c4182b3857cd,
title = "International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice",
abstract = "Over the past decades major improvements in the management of chemotherapy induced nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV can be prevented in almost 70{\%}, and even up to, 80{\%} of patients. Treatment guidelines enable physicians to integrate the latest clinical research into their daily practice. The large volume of rapidly evolving clinical data has been summarised and incorporated into treatment recommendations by well-known and reliable institutions. These organisations include the Multinational Association of Supportive Care in Cancer (MASCC), the European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN). However, despite the availability of these guidelines, there is an emerging evidence that adherence to, and implementation of, treatment recommendations is less than optimal. This review will especially focus on the content of the current antiemetic guidelines and will address the important question of how these guidelines are implemented in routine practice.",
keywords = "5-HT serotonin receptor antagonists, Antiemetic therapy, ASCO antiemetic guidelines, MASCC/ESMO antiemetic guidelines, NCCN practice antiemesis guidelines, Neurokinin receptor antagonist",
author = "Karin Jordan and Gralla, {Richard J.} and Franziska Jahn and Alex Molassiotis",
year = "2014",
month = "2",
day = "5",
doi = "10.1016/j.ejphar.2013.09.073",
language = "English (US)",
volume = "722",
pages = "197--202",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV)

T2 - Content and implementation in daily routine practice

AU - Jordan, Karin

AU - Gralla, Richard J.

AU - Jahn, Franziska

AU - Molassiotis, Alex

PY - 2014/2/5

Y1 - 2014/2/5

N2 - Over the past decades major improvements in the management of chemotherapy induced nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV can be prevented in almost 70%, and even up to, 80% of patients. Treatment guidelines enable physicians to integrate the latest clinical research into their daily practice. The large volume of rapidly evolving clinical data has been summarised and incorporated into treatment recommendations by well-known and reliable institutions. These organisations include the Multinational Association of Supportive Care in Cancer (MASCC), the European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN). However, despite the availability of these guidelines, there is an emerging evidence that adherence to, and implementation of, treatment recommendations is less than optimal. This review will especially focus on the content of the current antiemetic guidelines and will address the important question of how these guidelines are implemented in routine practice.

AB - Over the past decades major improvements in the management of chemotherapy induced nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV can be prevented in almost 70%, and even up to, 80% of patients. Treatment guidelines enable physicians to integrate the latest clinical research into their daily practice. The large volume of rapidly evolving clinical data has been summarised and incorporated into treatment recommendations by well-known and reliable institutions. These organisations include the Multinational Association of Supportive Care in Cancer (MASCC), the European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN). However, despite the availability of these guidelines, there is an emerging evidence that adherence to, and implementation of, treatment recommendations is less than optimal. This review will especially focus on the content of the current antiemetic guidelines and will address the important question of how these guidelines are implemented in routine practice.

KW - 5-HT serotonin receptor antagonists

KW - Antiemetic therapy

KW - ASCO antiemetic guidelines

KW - MASCC/ESMO antiemetic guidelines

KW - NCCN practice antiemesis guidelines

KW - Neurokinin receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=84892883297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892883297&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2013.09.073

DO - 10.1016/j.ejphar.2013.09.073

M3 - Article

VL - 722

SP - 197

EP - 202

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -